Physician profile
Amanda Barson
NPI 1053183095
$3,171.90
in general payments reported to CMS, 2019-2025
30 companies · $1,503 in 2025
The $1,503 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $228 · 2024: $1,441 · 2025: $1,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,171.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $349.37 | 2023-2025 | Airsupra, Farxiga, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $311.82 | 2024-2025 | Glassia, Aralast, Trintellix |
| Amgen INC. | $298.14 | 2023-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $288.33 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $266.21 | 2024-2025 | Rexulti |
| Pfizer INC. | $206.61 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $200.13 | 2024-2025 | Caplyta |
| Lundbeck LLC | $195.64 | 2024-2025 | Rexulti, Vyepti, Brintellix |
| Axsome Therapeutics, INC. | $152.50 | 2025 | Auvelity, Symbravo, Sunosi |
| Lilly USA, LLC | $118.81 | 2023-2025 | Zepbound, Mounjaro, Kisunla |
| Corcept Therapeutics | $100.36 | 2023 | Korlym |
| Novo Nordisk INC | $97.16 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Aimmune Therapeutics, INC. | $78.75 | 2024-2025 | Zenpep |
| Xeris Pharmaceuticals, INC. | $46.85 | 2024-2025 | Recorlev |
| Cranial Technologies, INC | $45.40 | 2024-2025 | Doc Band |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $43.15 | 2023-2025 | Livalo, Zoryve |
| Sumitomo Pharma America, INC. | $42.63 | 2024 | Gemtesa |
| Antares Pharma, INC. | $40.73 | 2024 | Xyosted |
| Esperion Therapeutics, INC. | $34.79 | 2023-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.32 | 2023-2025 | Xifaxan |
| Edwards Lifesciences Corporation | $29.35 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Exact Sciences Corporation | $28.88 | 2024 | Cologuard Collection Kit |
| Genzyme Corporation | $28.86 | 2025 | |
| Ibsa Pharma INC. | $24.55 | 2025 | Tirosint, Flector, Licart |
| Hologic Sales and Service, LLC | $23.29 | 2024 | Thinprep 2000 Processor, Aptima |
| Abbott Laboratories | $20.78 | 2024 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $18.60 | 2024 | Isturisa, Signifor Lar |
| Boston Scientific Corporation | $18.00 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.43 | 2023 | Quviviq |
| Medtronic, INC. | $15.46 | 2025 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Barson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.